EpiCept Corporation files for EU marketing approval of Ceplene

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
GE Opens First New Manufacturing Operation in Louisville, Ky...
Get set for Bupa Great Birmingham Run...
New Regional Aircraft Contracts and Support...
Harris Corporation's John Shipley Honored by U.S...
Farmers can use red diesel to help out during extreme weather...
Hogan Lovells' It's Not Just Peanuts Campaign Wins Legal Business...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

EpiCept Corporation files for EU marketing approval of Ceplene
EpiCept Corporation (Nasdaq and OMX Stockholm: EPCT), an emerging speciality pharmaceutical company, said on 9 October that it has applied for marketing approval of Ceplene (histamine dihydrochloride), its lead oncology product candidate, in the European Union.
The company has submitted a...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search